Structure-Guided Discovery of a Nonpeptidic MT5-MMP Inhibitor

  • ACS Med Chem Lett. 2026 May 25;17(6):1407-1415. doi: 10.1021/acsmedchemlett.6c00219.
Antoine Magniez  1 Johanna Giovannini  1 Pauline Zipfel  1 Chloé Rémondin  1 Hassiba Saïdoun  1 Audrey Davis  1 Santiago Rivera  2 Patrick Dallemagne  1 Christophe Rochais  1 Alban Lepailleur  1
Affiliations
  • 1. Université Caen Normandie, Normandie Univ, CERMN UR4258, F-14000 Caen, France.
  • 2. Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, 13284 Cedex 07 Marseille, France.
Abstract

Membrane type 5-matrix metalloproteinase (MT5-MMP, MMP-24), an η-secretase involved in amyloid precursor protein processing, is a promising but unexplored target in Alzheimer's disease. We report here the identification of a first nonpeptidic hit for MT5-MMP through a structure-guided approach. A homology model of the MT5-MMP catalytic domain was built from the MT3-MMP/batimastat structure and validated by both docking and experimental inhibition data obtained with batimastat (IC50 = 3 nM). To account for binding-site plasticity, especially that of the S1' pocket, molecular dynamics and ensemble docking were applied to a zinc-binding group (ZBG)-focused library of 3851 compounds. Although the initial screening campaign yielded only weakly active candidates, analysis of docking poses identified a relevant scaffold for optimization. Replacement of a carboxylic acid ZBG by a hydroxamic acid led to compound 17, which inhibited MT5-MMP with an IC50 of 6 μM and established a first nonpeptidic hit for future optimization.

Keywords
Alzheimer’s disease; MT5-MMP; metalloprotease inhibitor; molecular docking; zinc-binding group; η-secretase.
Products